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ABSTRACT Voltage-gated K1 channels of the Kv7 (KCNQ) family have important physiological functions in both excitable and
nonexcitable tissue. The family encompasses ﬁve genes encoding the channel subunits Kv7.1–5. Kv7.1 is found in epithelial and
cardiac tissue. Kv7.2–5 channels are predominantly neuronal channels and are important for controlling excitability. Kv7.1
channels have been considered the only Kv7 channels to undergo inactivation upon depolarization. However, here we dem-
onstrate that inactivation is also an intrinsic property of Kv7.4 and Kv7.5 channels, which inactivate to a larger extent than Kv7.1
channels at all potentials.Wedemonstrate that at least 30%of these channels are inactivatedat physiologically relevant potentials.
The onset of inactivation is voltage dependent and occurs on the order of seconds. Both time- and voltage-dependent recovery
from inactivation was investigated for Kv7.4 channels. A time constant of 1.476 0.21 s and a voltage constant of 54.96 3.4 mV
were determined. It was further demonstrated that heteromeric Kv7.3/Kv7.4 channels had inactivation properties different from
homomeric Kv7.4 channels. Finally, the Kv7 channel activator BMS-204352 was in contrast to retigabine found to abolish
inactivation of Kv7.4. In conclusion, this work demonstrates that inactivation is a key regulatory mechanism of Kv7.4 and Kv7.5
channels.
INTRODUCTION
The Kv7 family of ion channels has received much attention
since they have been identiﬁed as the molecular correlates of
several important human K1 conductances. The Kv7 family
is unique in the sense that mutations in four of the ﬁve genes
have been linked to human hereditary diseases (1,2). Within
the Kv7 family the most thorough characterization has been
performed on the Kv7.1 channel (for a recent review see
Jespersen et al. (3)). It was cloned in 1996 from patients suf-
fering from the proarrhythmic condition long QT syndrome
(4) and later demonstrated to associate with the b-subunits
KCNE1 to constitute the cardiac IKs current (5,6).
The neuronal M-current was ﬁrst described in 1980 as
slowly activating, noninactivating K1 current, which could
be inhibited through activation of muscarinic receptors (7).
The molecular component behind the M-current was later
identiﬁed as Kv7.2 and Kv7.3, and it has been demonstrated
how mutations in these genes are linked to a neonatal form of
epilepsy (8–12). Kv7.4 was cloned in 1999 and mutations in
this gene have been associated with deafness (13–15). Kv7.5,
like Kv7.2–4, is primarily neuronal, although no disease has
yet been associated to mutations in this gene (16–18).
Due to the tight coupling of Kv7 channels to dysfunction
and disease, great effort has been invested to understand the
regulation of these channels. Kv7.1 channels are modulated
by a number of factors including protein kinase A (PKA) and
protein kinase C (PKC), cell volume changes, external acid-
iﬁcation, and phosphatidyl inositol phosphate (PIP2) (19–24).
Additionally, Kv7.1 channel activity can be regulated by inter-
action with all members of the KCNE family of b-subunits
(5,6,25–28).
As the molecular correlates of the M-current, Kv7.2 and
Kv7.3 can be inhibited via muscarinic M1 receptor activation,
although inhibition of the M-current can also be achieved
through activation of other G-protein coupled receptors
(29–31). PIP2 has been demonstrated to be the link between
muscarinic receptors and the M-current (32–35), and it is
necessary for maintaining channel activity. Kv7.4 channels
are regulated by factors such as PKA, PKC, intracellular
Ca21, changes in cell volume, PIP2, and phosphorylation by
glucocorticoid-inducible kinases (19,36,37). Finally, changes
in cell volume, extracellular Zn21, acidiﬁcation, and musca-
rinic receptor activation modulate Kv7.5 (16,17). In addition
to the described regulations, Kv7 channel activation is voltage
dependent. A common feature is an initial opening at poten-
tials around 60 mV and a slow time constant for both ac-
tivation and deactivation compared to other voltage-gated K1
channels.
One biophysical parameter that differentiates the Kv7
channel subtypes is inactivation. Inactivation has been reported
for Kv7.1 channels and has been demonstrated to be time and
voltage dependent (5,6). Coassembly with either KCNE1 or
KCNE4 b-subunits can eliminate Kv7.1 channel inactiva-
tion (38–40). In contrast, it is generally believed that Kv7.2-5
channels—along with the M-current—do not inactivate (7,11,
13,17,18,39). However, a recent report shows that the activity
of Kv7.4 channels can be augmented by hyperpolarizing
prepulses, indicating that they may undergo inactivation (37).
We have devoted this study to a thorough investigation of the
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possible inactivation properties of all the Kv7 channels with
emphasis on Kv7.4 channels.
MATERIALS AND METHODS
Molecular biology
cRNA was synthesized by standard T7 in vitro run-off transcription of
human Kv7.1, Kv7.2, Kv7.3, and Kv7.4 and murine Kv7.5. A total of 50 nl
of ;0.5 mg/ml cRNA was injected into stage V–VI oocytes isolated from
Xenopus laevis according to national guidelines. Oocytes were kept at 19C
in Kulori solution (in mM: 90 NaCl, 1 KCl, 1 MgCl2, 1 CaCl2, 5 HEPES,
pH 7.4) and currents could be detected after 2–3 days.
Electrophysiology
Conventional two-electrode voltage-clamp recordings were conducted at
room temperature in Kulori solution using a Dagan CA-1D ampliﬁer
(Minneapolis, MN) and Pulse software (HEKA, Lambrecht/Pfalz, Germany).
The borosilicate electrodes were ﬁlled with 1 M KCl and had a tip resistance
of 0.5–2 MV. All drugs were dissolved in dimethylsulfoxide (DMSO) and
diluted so the ﬁnal DMSO concentration was,0.3%. At this concentration no
vehicle effects were observed. Retigabine, BMS-204352, and XE-991 were
synthesized at NeuroSearch A/S.
Calculations
Data were obtained from more than one batch of oocytes, and analyses were
performed in SigmaPlot. Data analyses were done with the Marquardt-
Levenberg algorithm, and decaying currents were best ﬁtted to a three-
parameter single exponential function: I(x) ¼ AN 1 A 3 exp(x/t). Rising
currents were best ﬁtted to a three-parameter single exponential function:
I(x) ¼ A0 1 A 3 (1  exp(x/t). For both equations I(x) is the current at
time or voltage x, A is the amplitudes of the exponential, and t is the time
or voltage constant. For functions describing an exponential decline AN is
the horizontal asymptotic value at time N, and for those describing an
exponential rise A0 is the current amplitude at time 0. The percentage of
control are calculated as the Ix/ICTRL 3 100%, where Ix is the normalized
current amplitude after retigabine, XE-991, or BMS-204352 application and
ICTRL is the corresponding current amplitude recorded in Kulori solution.
Normalization is done to the current amplitude recorded at Vact ¼ 140 mV
after a Vpre of 120 mV. The linear curve ﬁts on the percentage of control
data for the pharmacological experiments are ﬁtted to p(x) ¼ ax1 b, where
p(x) is the percentage of control at potential x, a is the slope, and b the
crossover point of x ¼ 0. Values are given as mean 6 SE where n indicates
the number of observations, and the mean is calculated as the mean of the
particular parameter from several individual ﬁts.
RESULTS
Inactivation properties of homomeric
Kv7.1-5 channels
The extent of inactivation of homomeric Kv7.1, 2, 4, and 5
channels was investigated by two-electrode voltage clamp
experiments in Xenopus oocytes. After injection of the
respective cRNAs, typical Kv7 currents could be activated
by standard voltage-step protocols consisting of a 3-s prepulse
at 80 mV (Vpre), a 2-s activation pulse at gradually more
positive potentials from 100 to 160 mV in 20-mV in-
crements to activate the channels (Vact), and ended by a 1-s
step to30 mV to facilitate recording of the tail current (Fig.
1, A–D). Water-injected control oocytes did not give rise to
interfering currents. From such experiments, the inactivation
of the Kv7 channels is normally not visible, although in-
dication of an inactivation process can be seen from a small
hook on the tail current indicative of a release from in-
activation (e.g., Fig. 1, A and D).
To study this phenomenon in more detail, we designed
the inactivation protocol shown in Fig. 2 with an initial
FIGURE 1 Two-electrode voltage-clamp ex-
periments on Kv7.1, 2, 4, and 5 homomeric
channels in Xenopus oocytes (A–D). The
channels were activated by voltage steps from
80 mV to potentials ranging from 100 to
160 mV in 20-mV increments (2-s duration),
and tail currents were measured at 30 mV.
Indications of an inactivation process of Kv7.1
and Kv7.5 can be seen by the small hook on the
tail current caused by release from inactivation
during the initial phase of the 1-s pulse to 30
mV as well as the marked difference in activa-
tion/deactivation kinetics.
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20-s-duration Vpre to clamp the cell membrane at holding
potentials of 120 mV to 160 mV in 20-mV increments.
This step was followed by a Vact step to140 mV. During the
5-s test pulse at 140 mV the noninactivated channels do
activate fully, but since they also to some degree inactivate
during the test pulse, we use the peak current as a measure of
available channels. Due to the channels inactivating during
the upstroke of the test current, the protocol may tend to
overestimate the degree of inactivation. Plotting the maximal
current amplitudes measured during the Vact step to140 mV
as a function of the preceding Vpre holding potential clearly
revealed the steady-state inactivation of homomeric Kv7.1,
Kv7.4, and Kv7.5 (Fig. 2, A–D). At physiologically relevant
potentials, inactivation was most pronounced for Kv7.4 and
Kv7.5, which displayed an inactivation of ;30% at Vpre ¼
50 mV when compared to Vpre ¼ 120 mV (Fig. 2 E).
These experiments demonstrate that in a typical resting
neuron (Vm ; 70 mV), signiﬁcant Kv7 channel inactiva-
tion occurs. For the following in-depth investigations, we
focused on Kv7.4.
Onset of inactivation
The onset of inactivation was studied by a three-step protocol
consisting of a 10- or 20-s prepulse clamping the cell mem-
brane at 120 mV to recover from inactivation, followed by
a step to 0 mV of variable duration (0–28 s in 2-s incre-
ments), allowing different degrees of channel inactivation,
and ﬁnally a 5-s step to140 mV (Fig. 3 A). The time-depen-
dent onset of inactivation is shown by plotting the maximal
current amplitude recorded at the Vact step to 140 mV as a
function of the time spent at 0 mV (Fig. 3 B). The results
could best be ﬁtted to a three-parameter one-exponential
function: I(x) ¼ AN 1 A 3 exp(x/t), which gave a mean
decay time constant, t, of 9.55 6 1.14 s, a noninactivation
component, AN, of 31%6 2.8%, and a relative amplitude of
FIGURE 2 Magnitude of inactivation. (A–D)
The inactivation properties of homomeric
Kv7 channel complexes were investigated by
voltage-clamp experiments in Xenopus oo-
cytes. After a 20-s-long prepulse at potentials
ranging from 120 mV to 160 mV (Vpre), the
maximal current amplitudes were measured
during a 5-s pulse at 140 mV (Vact) for each
channel subtype: A. Kv7.1, B. Kv7.2, C. Kv7.4,
and D. Kv7.5 (inset shows the voltage proto-
col). (E) The degree of inactivation of each Kv7
channel complex is revealed by plotting the
current amplitude normalized to the level
measured after a Vpre of120 mV as a function
of the preceding Vact potential. Maximal inac-
tivation of ;80% is observed for Kv7.5 at
160 mV.
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the inactivating current, A, of 72% 6 3.5%, n ¼ 7. To
investigate if the 10-s prepulse at120 mV was long enough
to facilitate full recovery from inactivation, we repeated the
experiment with a Vpre at120 mV of 20 s. This resulted in a
signiﬁcantly faster inactivation (t of 5.06 6 1.10 s, n ¼ 3;
P, 0.05, Student’s t-test) and a signiﬁcantly lower maximal
inactivation and amplitude of the exponential (AN ¼ 48%6
4.3%, P, 0.01 and A¼ 51%6 3.9%, P, 0.05), indicating
that some inactivation must remain even during a 10-s
prepulse at 120 mV (Fig. 3 B).
Time-dependent recovery from inactivation
The time-dependent recovery from inactivation of Kv7.4
was studied by a two-step protocol composed of a 20-s-long
prepulse at120mV followedby a 5-s activation pulse to140
mV (V1act). During this ﬁrst depolarizing pulse the channels
inactivate. To quantify the time needed to recover from in-
activation, this pulse was followed by a hyperpolarizing step to
120 mV ranging from 250 ms to 3750 ms in 250-ms
increments. The recovery from inactivation is reﬂected in the
current amplitude elicited by a second pulse to140mV (V2act)
(Fig. 4 A). A clear time-dependent recovery from inactivation
was shown by plotting the current amplitude of V2act in
percentage of the precedingV1actmaximal current amplitude as
a function of the time spent at 120 mV. This could best be
ﬁtted to a rising three-parameter one-exponential functionwith
a timeconstant of 1.476 0.21 s, anA0 of 69.8%6 2.6%, and an
A of 24.8%6 3.0%, n ¼ 7 (Fig. 4 B).
Voltage-dependent recovery from inactivation
Not only increasing time but also increasing hyperpolariz-
ing potentials would be expected to release the inactivation
of Kv7.4. We employed a protocol similar to that shown in
Fig. 4, but the time between V1act and V2act ﬁxed at 3 s. The
variable parameter in this experiment was the holding po-
tential of the intermediate hyperpolarizing step that releases
the inactivation, which was clamped at potential ranging
from 30 to 120 mV (Fig. 5 A). Similar to the time de-
pendence experiments, we plotted the maximal current am-
plitude of V2act in percentage of the V1act maximal current
amplitude but now as a function of the holding potential of
the intermediate hyperpolarizing step (Fig. 5 B). Fitting these
FIGURE 3 Time dependence of inactivation. (A)
The onset of inactivation of Kv7.4 at 0 mV was studied
by a two-step protocol designed to allow the channels
to inactivate increasingly. The inset in B shows the
voltage protocol employed, which clamped the cell
membrane at 120 mV for 20 s to allow for recovery
from inactivation (Vpre), followed by a step to 0 mV of
0–28-s duration in 2-s increments. The second step was
a depolarizing step to 140 mV for 5 s during which
the maximal current amplitude was measured. This
experiment was also performed with a 10-s-long Vpre
(current traces not shown). (B) Plotting the maxi-
mal current amplitude normalized to the amplitude at
V0 mV, 0 s as a function of the time spent at 0 mV
revealed a single-exponential correlation of the onset of
inactivation for both protocols. Fitting the data from the
two experiments to I(x) ¼ AN 1 A 3 exp(x/t) gave
signiﬁcantly different time constants: t10 s prepulse ¼
9.556 1.14 s (n ¼ 7) and t20 s prepulse ¼ 5.066 1.10 s
(n¼ 3); P, 0.05, t-test. The curves are generated from
the ﬁtted parameters.
2750 Jensen et al.
Biophysical Journal 92(8) 2747–2756
data to a three-parameter one-exponential decaying func-
tion resulted in a voltage constant of 54.9 6 3.4 mV, AN ¼
39.7% 6 3.7%, and A ¼ 6.0% 6 0.88%, n ¼ 10 (Fig. 5 B).
Kv7.3 modulates the Kv7.4 inactivation
As Kv7.3 and Kv7.4 can form functionally distinct hetero-
mers (13), we wanted to investigate the inactivation prop-
erties of coexpressed Kv7.3 and Kv7.4, and we did this by a
protocol comparable to the one shown in Fig. 2 (Fig. 6 A). A
signiﬁcant difference in the inactivation properties of
homomeric Kv7.4 versus heteromeric Kv7.314 channels
was evident in the range 40 mV–160 mV when plotting
the maximal current amplitude of the Vact step as a function
of the Vpre potential (Fig. 6 B). In contrast to homomeric
Kv7.4 channels, which display a ﬂat S-shaped course in the
inactivation behavior with no local maximum, heteromeric
Kv7.314 channels display less inactivation between Vpre
of 20 mV and 140 mV where the maximal amplitude
reaches 89.0%6 3.5%, n¼ 10 at Vpre¼120 mV relative to
Vpre ¼ 120 mV (homomeric Kv7.4 amplitude at Vpre ¼ 20
mV is 65.7% 6 2.8%, n ¼ 27 relative to Vpre ¼ 120).
Pharmacological modulation of inactivation
A handful of compounds has been used to address the
function of Kv7 channels (e.g., retigabine, XE-991, and
BMS-204352). The positive modulator retigabine presently
undergoing clinical phase III studies has especially been the
subject of intense study. It has been shown that retigabine
enhances the open probability, shifts the activation curve
leftward, and increases the macroscopic current of Kv7
channels (16,41–44). However, none of these studies has
investigated the effect on the inactivation of Kv7.4. To
address this we employed the standard inactivation voltage
protocol, as used in Figs. 2 and 6, in the absence and
presence of 10 mM retigabine (Fig. 7, A and B). The two
curves describing the measured currents at each potential
normalized to the control current at 120 mV and plotted as
a function of Vpre were parallel over the range of Vpre tested
(120 mV–180 mV) (Fig. 7 E). When plotting the
retigabine-induced current relative to the control current at
each potential the modulation of inactivation by retigabine
was also minor (the potentiation ranged from 170% 6 15%
at a Vpre of 120 mV to 269% 6 50% at a Vpre of 180 mV,
n ¼ 7). We quantiﬁed this as the slope of the best linear ﬁt
to the percentage of control data, which was calculated as
aRTG ¼ 0.33% 6 0.21%/mV, n ¼ 7 (Fig. 7, E–G).
In a similar manner we tested if the inhibitory effect of
XE-991 was related to a changed inactivation. Hence, 100
mM XE-991 was applied as described above, and the rate of
inactivation of Kv7.4 was compared before and after drug
application (Fig. 7, A and D). As with retigabine, the
maximal current amplitude relative to control conditions
over the range of Vpre tested was close to parallel and in the
range of 40%–45% (45% 6 4.3% at Vpre ¼ 120 mV to
FIGURE 4 Time-dependent recovery from inactivation
of Kv7.4. (A) The time course of recovery from inactiva-
tion was studied by a two-step protocol in which two
activating pulses follow a 20-s-long hyperpolarizing pulse
at 120 mV. Each 140-mV pulse (V1act and V2act) is of
5-s duration, and the variable parameter is the length of the
separating 120 mV hyperpolarizing pulse. The duration
of the hyperpolarizing pulse ranges from 250 ms to 3750
ms in 250-ms increments (inset shows the voltage proto-
col). (B) The maximal current amplitude at V2act is de-
picted in percentage of the maximal current amplitude at
V1act subtracting the A0 (the calculated current amplitude in
percentage at time 0) as a function of the release time at
120 mV (i.e., I[V2act]/I[V1act] 3 100%  A0), and this
revealed a single-exponential relationship between the
release time and the degree of recovery from inactivation.
Fitting the data to I(x) ¼ A01 A3 (1 exp(x/t)) gave a
time constant t ¼ 1.47 6 0.21 s (n ¼ 7). The curve is
generated from the ﬁtted parameters.
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45%6 8.6% at Vpre¼180 mV, n¼ 5). The slope of the best
linear ﬁt was calculated to aXE-991 ¼ 0.016% 6 0.017%/
mV, n ¼ 5 (Fig. 7, E–G).
BMS-204352 was originally developed for the treatment
of stroke, and the mechanism was thought to be by opening
BK channels (45). However, it has also been shown to be a
potent activator of Kv7 channels (41,46,47). A detailed
characterization of the mode of action on the Kv7 channels
has not yet been described, so we investigated the effect of
BMS-204352 on the inactivation properties of Kv7.4. A total
of 10 mM BMS-204352 potentiated the current to 690% 6
106%, n¼ 5 of control measured at the end of a depolarizing
step during the following repeated voltage protocol: 4 s at
80 mV, 2 s at140 mV, and 1 s at30 mV (not shown). In
contrast to retigabine and XE-991, a clear effect on
inactivation was observed with BMS-204352 (Fig. 7, A
and C). The maximal Vact current amplitude increased over
the range of Vpre tested from 578%6 15% of control at Vpre¼
120 mV to 1745%6 422% at Vpre ¼180 mV, n ¼ 3. The
slope of the best linear ﬁt of the percentage of control data
reﬂects abolishment of Kv7.4 inactivation by BMS-204352,
as it was calculated to aBMS ¼ 5.24% 6 1.51%/mV, n ¼ 3
(Fig. 7, E–G).
DISCUSSION
The nonneuronal Kv7.1 potassium channel has been de-
scribed to inactivate (38,39,48), whereas the general notion
has been that the other Kv7 family members do not in-
activate. Contrary to this general view on the biophysical
properties of the neuronal Kv7 channels, we here show that
Kv7.4 and Kv7.5 channels indeed do inactivate. We have
performed detailed studies on Kv7.4 showing that the mac-
roscopic inactivation is voltage dependent and is augmented
as a function of increased holding potentials, reaching a maxi-
mum .60% at 180 mV. Kv7.4, as well as Kv7.5 channels,
was found to inactivate to a larger extent than Kv7.1.
The kinetics of Kv7.4 channel inactivation is slow, with
time constants of 5–10 s depending on the duration of the
preceding hyperpolarizing pulse (t10 s prepulse ¼ 9.55 6
1.14 s and t20 s prepulse ¼ 5.06 6 1.10 s). Recovery from
inactivation of Kv7.4 is both time and voltage dependent.
When inactivation was released by hyperpolarizing pulses at
120 mV at increasing time intervals, the recovery from
inactivation was clearly time dependent with a time constant
of 1.47 6 0.21 s. The inactivation kinetics of Kv7.4 is ap-
parently much slower than that of Kv7.1, as Tristani-Firouzi
and Sanguinetti found that Kv7.1 inactivates monoexponen-
tially at 120 mV with a time constant of 130 ms after an
initial delay of;75 ms (38). The time constants for recovery
from inactivation of Kv7.1 was likewise much faster, ranging
from 30–40 ms and showing very little voltage dependence
at voltages ranging from 90 to 30 mV (38). However,
since the kinetics of inactivation and recovery from inacti-
vation in their study was determined from the hooked tail
current, they may only reﬂect the early phase of both
FIGURE 5 Voltage-dependent recovery from inac-
tivation of Kv7.4. (A) The kinetics of recovery from
inactivation was studied by a two-step protocol similar
to the one used in the time-dependent recovery
experiments, but with the duration of the release pulse
ﬁxed at 3 s. The variable in this experiment was the
voltage employed to clamp the membrane during the
release pulse, which ranged from120 mV to30 mV
in 10-mV increments (inset shows the protocol). (B)
The maximal current amplitude recorded at V2act in
percentage of the corresponding amplitude of V1act
plotted as a function of the holding potential of the
release pulse could best be ﬁtted to a single-exponential
function: I(x) ¼ AN 1 A 3 exp(x/t), resulting in a
voltage-constant t ¼ 54.9 6 3.4 mV (n ¼ 10).
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phenomena. The degree of Kv7.1 inactivation in both studies
was found to be ;35% at 140 mV with a similar voltage
dependence despite the different protocols used to reﬂect the
inactivation.
It has been demonstrated that Kv7.3 and Kv7.4 can form
functional heteromers (13), so we investigated if such com-
plexes had an inactivation proﬁle different from Kv7.4
homomers. The quantity of inactivated heteromers was sig-
niﬁcantly decreased at potentials from 40 mV to1 60 mV.
This indicates that more active Kv7.31 Kv7.4 channel com-
plexes will be present at these potentials relative to homomeric
Kv7.4 channels.
In a ﬁnal investigation we addressed if different Kv7
channel modulators had any impact on the inactivation prop-
erties of the channels. It was demonstrated that the Kv7.4
channel activator retigabine and the inhibitor XE-991 did
not mediate their effects through changed inactivation. In
contrast, BMS-204352 abolished the inactivation of Kv7.4
channels. These data demonstrate that the Kv7 openers
retigabine and BMS-204352 have distinct modes of action.
It is known from Kv7.1 inactivation that this can be abol-
ished by coexpression with KCNE1 (minK), which is in
agreement with the notion that the endogenous IKs current
does not inactivate (38). It has been suggested that this
modiﬁcation of the channel kinetics is accomplished by the
C-terminus of KCNE1 protruding into the Kv7.1 complex
and binding to the pore loop (49). The modest effect of
Kv7.3 and retigabine as opposed to the strong effect of BMS-
204352 on Kv7.4 inactivation may likewise be caused by the
physical interaction resulting in an allosteric modulation of
the channel complex. However, we do not know the speciﬁc
binding sites of these molecules to the Kv7.4 complex. It is
likely that BMS-204352 binds to a site other than retigabine,
since they are structurally quite different molecules. Fur-
ther, the two compounds modify the Kv7 channel subtypes
differentially since BMS-203352 blocks Kv7.1 whereas
retigabine shows no effect on this channel (44,50). Likewise,
the drugs show differential effects on the neuronal Kv7
channels (51).
One of the ways a drug can activate an ion channel is by
removing its inactivation, as is the case for BMS-204352.
The effects of BMS-204352 is, however, signiﬁcantly larger
than what can be accounted for by reduced inactivation alone
(Fig. 7). The compound also activates the Kv7.4 channel by
shifting the voltage-dependent activation curve toward nega-
tive values (50) as well as by activating a voltage-independent
Kv7.4 current (41). Since the open probability of Kv7.4
channels at positive membrane potentials is only ;0.18 (52),
there is room for an increased opening of the channel in the
presence of compound, which must also occur for the current
to increase by more than ﬁvefold at the noninactivation poten-
tial of 120 mV.
In this study Kv7.4 and Kv7.5 are found to inactivate to
the largest degree, whereas Kv7.2 does not inactivate. Kv7.4
and Kv7.5 exhibit a number of similar characteristics in
contrast to Kv7.2: Kv7.4 has a greater amino acid sequence
homology with Kv7.5 than with Kv7.2; pharmacologically
BMS-204352 activates Kv7.4 and Kv7.5, whereas it does
not modify Kv7.2/3 (50); biophysically the unitary currents
of Kv7.4 and Kv7.5 are 2.1 and 2.2 pS, whereas that of
Kv7.2 is 6.2 pS (52,53); the maximal open probability of
Kv7.4 and Kv7.5 are 0.18 and 0.17, respectively, whereas it
is 0.07 for Kv7.2. This does not in itself explain why Kv7.4
and Kv7.5 inactivate and Kv7.2 does not, and to address this
question it is important to study the residues in the Kv7 chan-
nels involved in the inactivation process of which we currently
have no clear indication.
This study shows that Kv7.4 channel inactivation is
different from classical N- and C-type inactivation found in
FIGURE 6 Kv7.314 heteromers inactivate differently from Kv7.4 ho-
momers. (A) Cells expressing heteromeric Kv7.314 channels were inves-
tigated for the inactivation behavior of the respective channels with the same
voltage protocol as in Fig. 2 (expanded to include a prepulse step to 180
mV). (B) The ﬁgure shows the normalized maximal current recorded at a
5-s-long depolarizing pulse to 140 mV preceded by a 20-s-long prepulse
(Vpre) ranging from 120 mV to 180 mV in 20-mV increments for both
Kv7.4 and Kv7.3 1 4. Current amplitudes are plotted as a function of the
holding potential during the 20-s-long prepulse, and the two channel
complexes are signiﬁcantly different in this respect after a prepulse rang-
ing from 40 mV to 160 mV. Asterisks indicate the level of signiﬁcance
(*, P , 0.05; **, P , 0.005, t-test, n ¼ 10 and 27, Kv7.3 1 4 and Kv7.4,
respectively).
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voltage-gated Na1 channels and voltage-gated K1 channels
of the Shaker type (38,48,54–57). Features that distinguish
Kv7.4 inactivation from N- and C-type inactivation are slow
onset and voltage dependency. This is also true for Kv7.1
inactivation (38), suggesting that the inactivation mechanism
for these two Kv7 channel subtypes are similar.
The inactivation property may have important bearings for
the pathophysiology and pharmacology of the neuronal Kv7
channels. Within the family of Kv7 channels, inactivation at
physiologically relevant potentials was most prominent for
Kv7.4 and Kv7.5 channels. Of the ﬁve Kv7 channel sub-
units, Kv7.4 displays the most restricted expression pattern,
being present in the inner ear and the auditory pathways of
the brain but also in certain dopaminergic neurones (58,59).
Hence, Kv7.4 channels could represent a particularly rel-
evant target for treatment with drugs speciﬁcally activating
the Kv7.4 channel as efﬁcacy, and side effect proﬁles of such
a compound could prove superior to panreactive compounds
affecting all neuronal members of the Kv7 family.
In conclusion we have described inactivation as a new
regulatory mechanism for Kv7.4 and Kv7.5 channels. At
physiologically relevant resting potentials, the current is
reduced by more than 30% due to steady-state inactivation.
These results add to a more profound understanding of the
biophysical nature of the Kv7 channel family and their
physiological impact. Pharmacological channel modulators
inﬂuence the inactivation properties differentially, so this
newly discovered regulatory mechanism is of further im-
portance when developing drugs targeted for these channels.
Physiological signaling molecules may also inﬂuence the
steady-state inactivation of Kv7 channels, and if this proves
to be the case it will be an efﬁcient way of modulating
neuronal excitability.
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